SAN DIEGO (MedPage Today) — A combination of phentermine and topiramate (Qnexa) appears to induce weight loss and a decrease in metabolic risk parameters for cardiovascular disease in obese patients, researchers reported here. (Source: MedPage Today Endocrinology)
MedWorm Message: Register for MedMatcha, MedWorm’s m edical advertising network, and receive $5 free advertising.
The manufacturers of Vialipro, a dietary supplement marketed as a sexual enhancement, voluntarily recalled the product after FDA analysis revealed the capsule contained undeclared amounts of sulfoaildenafil, an analogue of the erectile dysfunction drug sildenafil (Viagra). (Source: MedPage Today Public Health)
GAITHERSBURG, Md. (MedPage Today) — An FDA advisory panel was divided over whether to recommend the approval of the investigational weight-loss drug phentermine/topiramate (Qnexa), but the Nay votes prevailed 10-6. (Source: MedPage Today Public Health)
MedWorm Message: Register for MedMatcha, MedWorm’s medical advertising network, and re ceive $5 free advertising.
Source: PharmaTimes
Area: News
PharmaT imes reports that advisers to the United States US Food and Drug Administration have voted 10-6 against recommending approval of the drug Qnexa® (phentermine/topiramate) for the treatment of obesity. Although the advisory panel did not dispute the effectiveness of the drug, the panel felt that the potential side effects such as depression, memory loss, increased heart rate and birth defects outweighed (more…)
Major Finding: In patients on the highest dose of phentermine plus controlled-release topiramate, systolic blood pressure reductions were significantly lower than with placebo: 3.4 mm Hg after 28 weeks in EQUATE, 3.8 mm Hg after 56 weeks in EQUIP, and 3.2 mm Hg after 56 weeks in CONQUER. (Source: Cardiology News)
A major retrospective study showed that men prescribed erectile dysfunction (ED) drugs such as sildenafil (Viagra) also had markedly h igher rates of sexually transmitted diseases (MedPage Today) — though the association could have more to do with behavior than ED drug use. (Source: MedPage Today State Required CME)
The highest dose of an investigational weight-loss therapy, a combination of very low-dose phentermine and controlled-release topiramate, reduces body weight by around 10% after a year of treatment…
For complete story visit theheart.org. (Source: theHeart.org)
MedWorm Message: Register for MedMatcha, MedWorm’s medical advertising network, and receive $5 free adver tising.
On Friday, an FDA advisory panel voted 11-0 against recommending FDA approval of a proposed treatment for hypoactive sexual-desire disorder, which decreases women’s sex drive, the Wall Street Journal reports. The R eproductive Health Drugs Advisory Committee reviewed an application seeking FDA approval of the drug flibanserin, also known as the “pink pill” or “female Viagra.” Although the agency is not required to follow the panel’s recommendation, (more…)
WASHINGTON (MedPage Today) — The U.S. Senate voted to delay a steep pay cut for doctors, but not before CMS began processing claims at the lower rate, an FDA panel approved a new morning-after pill and voted against “female Viagra“, and the agency fined the Red Cross for blood safety violations. (Source: MedPage Today Public Health)
GAITHERSBURG, Md. (MedPage Today) — An FDA advisory committee has decided that the makers of the investigational drug flibanserin (Girosa) — often dubbed the female Viagra — haven’t proved that the pill treats hypoactive sexual-desire disorder (HSDD) in women any better than placebo. (Source: MedPage Today P roduct Alert)